Cure My Disease

Don't miss your cure!

 Log in / Sign up

Phone app aims to help hearts stay in rhythm

NCT ID NCT06933615

Disease control Sponsor: Ege University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers at Ege University are testing a mobile phone program called m-BAFY that helps people with atrial fibrillation manage their condition at home. The app lets patients record symptoms and vital signs, sends personalized feedback, and provides guideline-based information on managing the disease. The study compares 90 patients who use the app for three months with those who receive standard care, looking at symptom severity, medication compliance, self-care ability, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a mobile app program for managing atrial fibrillation at home
What this could lead to
If the app helps, it could give people with atrial fibrillation a simple phone-based tool to track symptoms, stick to medication, and manage daily care between clinic visits.
What could go wrong
This is a small study of 90 people in one country, so the results may not apply broadly. An app can only help if people use it regularly, and some may find it hard to keep up with daily entries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Jun 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Being 18 years old and above * Having an AF diagnosis * Being literate * Being able to understand and speak Turkish * Being able to use a smartphone * Being willing to participate in the study Exclusion Criteria: * Hearing and speech problems * Cardiac surgery \< 3 months before the interview date * Presence of psychiatric disease * No data entry for at least 2 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

Contacts and locations

Locations

  • Ege University

    Izmir, Bornova, 35030, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.